Potential optimalisation of (Expediency) and Effectiveness of TNF-blockers

Potential optimalisation of (Expediency) and Effectiveness of TNF-blockers - POET

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON35995

Enrollment

1000

Registered

2011-09-20

Start date

2012-03-18

Completion date

Unknown

Last updated

2024-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

rheumatoid arthritis

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: •Diagnosis Rheumatoid Arthritis according to the 1987 ACR criteria •Treated for at least 1 year with a TNF-blocker and stable (no dose changes) DMARD treatment for the preceding 6 months •Low disease activity for at least 6 months, according to both patient and rheumatologist, and a DAS28

Exclusion criteria

Exclusion criteria: None

Design outcomes

Primary

Measure	Time frame
Primary outcome: the primary outcome measure is the percentage of patients who experience an exacerbation of RA during the first year: increase of DAS28 >3.2 with a delta DAS28 of > 1.2.	—

Secondary

Measure	Time frame
Number of patients stopped anti-TNF at 12 months Timespan of anti tNF usage, volume and medical costs DAS28 value Percentage of patients with a DAS28	—

Countries

Netherlands

Outcome results